Low dose weekly paclitaxel with radiation is an acceptable alternative for weekly cisplatin with radiation in the treatment of advanced head neck carcinoma: An observational study

Authors
Dr Md. Zillur Rahman Bhuiyan¹, Dr Ranada Prasad Roy², Dr Atiar Rahman³
¹Associate Professor, Dept. of Oncology, BSMMU
²Assistant Professor, Dept. of Radiation Oncology, NICRH
³Associate Professor, Dept. of Transfusion Medicine, BSMMU

Abstract
Introduction: In general head and neck cancer may be treated with single modality of treatment for early stage disease but may require multimodality treatment protocol for advanced disease. Concurrent chemoradiation is the current standard protocol for patients with locally advanced squamous cell carcinoma of head neck. Carcinoma of head and neck is a common clinical entity approximately 3.2% of the total new cancer cases. In Bangladesh, according to cancer Registry Report NICRH (2008-2010), approximately 2901(10.6%) patients are registered with head and neck cancer.

Study Design and Objective: This prospective observational study is to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven advanced squamous cell carcinoma of head neck.

Methods: All the patients were divided in two groups. Arm-A 30 number patients received injection Paclitaxel 40mg/m², i/v 1 hr. infusion weekly for 6 weeks and Arm- B 30 number patients received injection Cisplatin 30mg/m², i/v 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray(Gy) radiation at the rate of 2Gy/day 5# in a week for 6.5 weeks.

Results: In this study ninety percent (90%) patients were smoker. The most common presenting features were cervical lymphadenopathy (Arm A 100% vs. Arm B 100%), pain (Arm A 73.33% vs. Arm B 66.67%), sore throat (Arm A 36.67% vs. Arm B 36.66%), hoarseness of voice (Arm A 36.67% vs. Arm B 36.66%) etc. Complete response of patients treated with concurrent chemoradiation with inj. Paclitaxel was 63.33% in comparison to 53.33% complete response achieved in patients treated with concurrent chemoradiation with inj. Cisplatin. This difference was statistically not much more significant. Common toxicities related to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopenia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable.

Conclusion: In this study the clinical response and toxicities produced by weekly low dose paclitaxel with radiation in locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin schedule with radiation showed no additional efficacy. So, concurrent chemoradiotherapy with weekly Paclitaxel is suitable when Cisplatin is contraindicated for the patients with renal impairment.

Keywords: Paclitaxel and Cisplatin: (are anti cancer drugs). Gy(Gray): radiation unit. Concurrent chemoradiotherapy: when any anti cancer drug added during radiotherapy.

Introduction
Head neck carcinoma is the sixth most common cancer in the world. Approximately 50,000 patients are diagnosed annually with squamous cell head neck cancer in United States. Worldwide, approximately 600,000 patients are histopathologically detected. Nearly 60% of this
population present with locally advanced but non metastatic disease (Halperin et al. 2013). Head Neck cancer is more common in men. 66% to 95% of cases occur in men. The incidence of head and neck cancer increases with age, especially after 50 years of age. Although most patients are between 50 and 70 years age, younger patients can also develop head and neck cancer (Pazdur et al. 2010). The usual time of diagnosis is after the age of 40, except for salivary gland and nasopharyngeal cancers which may occur in younger age group (Devita and Rosenberg 10th ed. 2015).

Cancer is one of the major causes of morbidity and mortality among the non communicable diseases in Bangladesh. Each year more than 200,000 people develop cancer and 150,000 patients die from the disease. Cancer is the sixth cause of mortality in Bangladesh and more than half of the cancer patients die within five years of diagnosis. The number of people developing cancer is expected to increase in huge number mainly because of ignorance, poor socioeconomic status and some lifestyle factors. This is a contributory factor for more cancer load in Bangladesh; (National cancer control strategy and plan of action 2009 - 2015). The overall head and neck cancer remains a significant international health problem. The higher incidence of the disease in Bangladesh thought to reflect the prevalence of risk factors, such as betel nut chewing and use of smokeless tobacco. In united states, the higher incidence among urban males in thought to reflect exposure to tobacco and alcohol. Risk factors for head and neck cancer include tobacco and alcohol use, ultraviolet light exposure, viral infection and environmental exposures (Pazdur et al. 2010). Human Papillomavirus infection (HPV; most commonly HPV-16) plays a role in the development of certain head and neck cancers, particularly those in the oropharynx (Devita and Rosenberg 10th ed. 2015). More than 90% of malignancies are of squamous cell histology (Symonds et al. 2012). Cancers of the CNS, the eye, the esophagus, and the thyroid gland, as well as those of the scalp, skin, muscles, and bones of the head and neck, are not usually classified as head and neck cancers. Head Neck cancers encompass a diverse group that are oral cavity, oropharynx, larynx, nasopharynx, hypopharynx, paranasal sinuses, salivary glands and ear. Although the treatment for these area is often highly specialized, they also have many features is common with regard to investigation, diagnosis and management.

Head neck cancers staging is complex and depends on the anatomic location of the tumor for practical purposes, head neck cancers is divided into three clinical stages: early, locoregionally advanced, and recurrent or metastatic. Treatment approaches can vary depending on the disease stage. The majority of patients present with locoregionally advanced disease. Concurrent chemoradiotherapy has a central role in the management of locoregionally advanced head neck cancers and a survival benefit for this approach in comparison to radiation alone is now widely accepted. Overwhelmingly, trial results indicate that the concurrent addition of chemotherapy sensitize tumors to radiation and increases locoregional control and thereby survival. The concurrent administration of chemotherapy and radiation has improved outcomes in a variety of clinical scenarios. These include all but specially locally advanced nasopharyngeal carcinomas, advanced unresectable cancers, organ preservation in locally advanced larynx and base of the tongue cancers, and in high-risk post operative patients. Thus, concurrent chemoradiation is accepted as a standard option for these patients. Meta-analysis demonstrates that the addition of chemotherapy concurrent to radiation therapy results in up to a 4% to 8% absolute improvement in survival, which amounts to a 12% to 19% reduction in the risk of death, whether in definitive or post operative adjuvant setting (Skeel and khleif 2011).

Radiotherapy and concurrent chemotherapy represents the most commonly used strategy and is a more attractive approach because some
chemotherapeutic agents may have both radiosensitize cells and provide additive cytotoxicity (Halperin et al. 2013). Cisplatin improves the anti-tumor efficacy of radiation therapy. Also taxane-based chemotherapies emerged as one of the most powerful compounds that might improve loco-regional control. Paclitaxel is one of the most active agents for squamous cell carcinoma of head neck in the metastatic and recurrent setting and has been shown to be a radiosensitizer when paclitaxel (low dose) uses concurrently with radiation for human squamous cell carcinoma of head neck cell lines. Paclitaxel has high-affinity binding to microtubules enhances tubulin polymerization. Normal dynamic process of microtubule network is inhibited, leading to inhibition of mitosis and cell division (Chu and Devita, 2013).

In this study, we tried to show the comparative study analysis of response and acute toxicities during the treatment of squamous cell carcinoma of locally advanced head neck cancers with low dose weekly Paclitaxel with radiation (Arm-A) versus low dose weekly Cisplatin with radiation(Arm-B).

Methods
This was a prospective observational study with two comparison group which include low dose weekly paclitaxel with radiation in arm A and low dose weekly cisplatin with radiation in arm B to observe and compare the treatment effects, response rate and clinical outcome by two modalities of treatment planning. Patient with locally advanced squamous cell carcinoma of head neck treated with concurrent chemoradiation either by paclitaxel or cisplatin and had any part of their treatment at Bangabandhu Sheikh Mujib Medical University Dhaka, National Institute of Cancer Research & Hospital, Dhaka between June 2016 to May 2017 were enrolled in this study and were convinced to participate in the study after giving written informed consent and satisfying inclusion and exclusion criteria. In this study, total 60 patients of locally advanced squamous cell carcinoma of head and neck cancer were treated. Among them 30 patients who received Paclitaxel 40 mg/m2 I.V 1 hour infusion weekly for 6 weeks, (Arm A) and the rest 30 patients received Cisplatin 30mg/m2, I.V 2 hours infusion weekly for 6 weeks (Arm B). All patients received 66Gy concurrent radiation using a Tele Cobalt 60 Machine, at the rate of 2Gy/day, 5 fractions/week, over a period of 6.5 weeks.

Results
A total number of 60 patients were enrolled in this prospective observational study to compare the effectiveness, toxicity of low dose weekly Paclitaxel with radiation versus low dose weekly Cisplatin with radiation in the treatment of locally advance head neck carcinoma. Among 60 subjects, 30 subjects were in Arm-A, treated with concurrent chemoradiation with Paclitaxel and Arm-B 30 subjects treated with concurrent chemoradiation with Cisplatin. Subjects clinical condition was assessed. Then outcome of these two treatment techniques were studied. Following table showing the distribution of patients on the basis of different parameters/ variables.

Table 1: Distribution of the patients according to age

| Statistics                  | Arm A N=30 | Arm B N=30 | P-value |
|-----------------------------|------------|------------|---------|
| Age (Mean±SD)               | 54.2±7.52  | 50.23±8.73 |         |
| Age (Median range) in year  | 52.50      | 49.00      | 0.067   |

No statistically difference between the age of two group
### Table 2: Distribution of the patients according to the use of Oral Tobacco and Pan Masala

| Oral tobacco and pan masala use | Arm A | Arm B | Chi square test | P-value |
|--------------------------------|-------|-------|----------------|---------|
| Yes                            | 20    | 17    | 0.150          | 0.697   |
| No                             | 10    | 13    | 0.283          | 0.594   |
| Total                          | 30    | 30    | 100.0          | 100.0   |

No statistical difference was found between these two group

### Table 3: Distribution of patients according to the site of Primary Tumour

| Site              | No. of patients | Total no. of patients and Percentage (N=60) | Chi square test | P-value |
|-------------------|-----------------|---------------------------------------------|----------------|---------|
| Oral cavity       | 07 (n= 30)      | 15(25.00%)                                  | 0.053          | 0.817   |
| Nasopharynx       | 04 (n= 30)      | 10(16.66%)                                  | 0.343          | 0.558   |
| Oropharynx        | 03 (n= 30)      | 05(08.33%)                                  | 0.184          | 0.667   |
| Hypopharynx       | 01 (n= 30)      | 02(03.33%)                                  | 0              | 1       |
| Larynx            | 13 (n= 30)      | 25(41.66%)                                  | 0.028          | 0.866   |
| Others            | 02 (n= 30)      | 03(05.00%)                                  | 0.317          | 0.573   |

No statistical difference was found between these two group

### Table 4: Distribution of patients by Clinical Features (before treatment)

| Clinical features         | No. of patients | N=60 and % | Chi square test | P-value |
|---------------------------|-----------------|-------------|----------------|---------|
| Cervical lymphadenopathy  | 30 (n= 30)      | 60(100%)    | 0              | 1       |
| Pain                      | 22 (n= 30)      | 42(70.00%)  | 0.056          | 0.812   |
| Sore throat               | 14 (n= 30)      | 26(43.33%)  | 0.107          | 0.743   |
| Hoarseness of voice       | 14 (n= 30)      | 25(41.67%)  | 4.344          | 0.371   |
| Dysphagia                 | 09 (n= 30)      | 16(26.67%)  | 0.197          | 0.656   |
| Dyspnoea                  | 07 (n= 30)      | 13(21.67%)  | 0.063          | 0.801   |
| Cough                     | 03 (n= 30)      | 08(13.33%)  | 0.441          | 0.506   |
| Otalgia                   | 01 (n= 30)      | 03(05.00%)  | 0.317          | 0.573   |

### Table 5: Distribution of the patients according to Histopathological Grading

| Grading                          | Arm A | Arm B | Total | Chi square value | P-value |
|----------------------------------|-------|-------|-------|-----------------|---------|
| Well differentiated (Grade I)     | 2     | 3     | 5     | 8.33            | 0.184   | 0.667   |
| Moderately differentiated (Grade II) | 14   | 16    | 30    | 50.00           | 0.088   | 0.765   |
| Poorly differentiated (Grade III) | 11   | 9     | 20    | 33.33           | 0.150   | 0.698   |
| Not specified                    | 3     | 2     | 5     | 8.33            | 0.184   | 0.667   |
| Total                            | 30    | 30    | 60    | 100.0           | 100.0   |         |

No statistical difference was found between these two group

### Table 6A: Distribution of patients by treatment response in smoker

| Response                           | Arm-A Smoker n-27 | Arm-B Smoker n-27 | Chi square test | P-value |
|------------------------------------|-------------------|-------------------|----------------|---------|
| Complete response number           | 16                | 14                | 0.085          | 0.769   |
| Partial response number            | 11                | 13                | 0.115          | 0.734   |

No statistical difference was found between these two group
Table-6(B): Distribution of patients by treatment response in non-smoker

| Response                  | Arm-A Smoker n=27 | Arm-B Smoker n=27 | Chi square test | P-value |
|---------------------------|--------------------|--------------------|-----------------|---------|
| Complete response number  | 03                 | 02                 | 0.11            | 0.740   |
| Partial response number   | 00                 | 01                 | 0.875           | 0.349   |
| No statistical difference was found between these two group |

Table 7: Distribution of the patients by Treatment Response

| Status at last follow-up (After 24 weeks of Arm A Arm B Total | N | % | N | % | N | % |
|--------------------------------------------------------------|---|---|---|---|---|---|
| Complete response                                            | 19| 63.33 | 16| 53.33 | 35| 58.33 |
| Partial response                                             | 11| 36.67 | 14| 46.67 | 25| 41.67 |
| No response                                                  | 0 | 0 | 0 | 0 | 0 | 0 |
| Progressive disease                                          | 0 | 0 | 0 | 0 | 0 | 0 |
| Total                                                        | 30| 100.0 | 30| 100.0 | 60| 100.0 |

X2 = 0.061, Pvalue=0.432

Table 8: Distribution of the patients on Treatment Related Haematological and Non-Haematological Toxicities

| Variable       | Arm-A n=30 | Arm-B n=30 | (Chi square test) p-value |
|----------------|------------|------------|---------------------------|
| Mucositis Group I | 02 | 06.67 | 00 | 00.00 | 0.369 |
| Group II       | 12 | 40.00 | 08 | 26.67 |             |
| Group III      | 07 | 23.33 | 07 | 23.33 |             |
| No statistical difference between these two group |
| Skin reaction Group I | 08 | 26.66 | 18 | 60.00 | 0.240 |
| Group II       | 16 | 53.33 | 07 | 23.33 |             |
| Group III      | 06 | 20.00 | 05 | 16.66 |             |
| No statistical difference between these two group |
| Vomiting Group I | 01 | 03.33 | 07 | 23.33 | 0.511 |
| Group II       | 05 | 16.67 | 12 | 40.00 |             |
| Group III      | 02 | 06.67 | 03 | 10.00 |             |
| No statistical difference between these two group |

Discussion

The head and neck malignancies constitute about 6% of all cancer worldwide. Head and Neck hampers three of the vital functions such as voice, and swallowing by virtue of its anatomical location, local infiltration and direct extension. Incidence of head and neck cancer increases with age, especially after 50 years of age. Most patients are between 50 to 70 years old (Pazdur et al. 2010). In this study the patients aged between 17 years to 69 years with a mean age of 53.4 years. This is consistent with the above statement.

Head and Neck cancer is a predominantly male disease. As regards to sex of head and neck cancer have shown male and female ratio was 5:1 (Bomford et al. 2003) 66% to 95% of case occur in men (Pazdur et al. 2010).

Head and neck tumors occur six times more often among cigarette smokers than nonsmokers (Stupp R. ct al. 1994). In this study, among 60 patients 54(90%) were found smokers, which reflects the strong association of smoking with head and neck cancer.

Pain, sore throat and hoarseness of voice are the cardinal presenting symptoms of head and neck cancer. In this study, among the 60 cases 42(70%) cases presented with pain, 26(43.43%) cases presented with sore throat and 25(41.67%) cases...
presented with hoarseness of voice.
All the patients (100%) of this study presented with cervical lymphadenopathy. As only locally advanced head and neck cancer cases were taken as study population.
Dyspnoea occurs with advanced exophytic carcinoma where growth narrows the airway. Here 13 (21.67%) cases presented with dyspnoea. 8 (13.33%) with cough and 3 (5%) with referred otalgia.
Multimodality therapy is required for management of locally advanced head and neck cancer (stage III and stage IVA). Currently four multimodality treatment approaches are used. They are concurrent chemoradiation. Induction chemotherapy followed by radiotherapy. Radiotherapy alone and surgery followed by adjuvant concurrent chemoradiotherapy
Concurrent chemoradiotherapy is the standard care for patients with unresectable locally advanced squamous cell carcinoma of head and neck cancer. The optimal chemotherapy agents and their dose schedules have yet to be defined. Cisplatin improves the anti-tumour efficacy of radiation therapy with 5-year loco-regional control rates between 35-70%. The last decade witnessed the introduction of new chemotherapeutic agents, among these, taxane-based chemotherapies emerged as one of the most powerful compounds that might improve loco-regional control (Hoda et al. 2010). The aim of this study was to compare the outcome and toxicity of weekly Paclitaxel with weekly Cisplatin based concurrent chemoradiation in locally advanced squamous cell carcinoma of head and neck cancer.
Patients were evaluated weekly by history, physical examination and laboratory investigation during treatment period. The response evaluation was performed 6 weeks after the completion of concurrent chemoradiotherapy and every 6 weeks thereafter for six months. For the evaluation of tumour response, physical examination, radiologically image and panendoscopy when it was indicated, were performed, as well as CT and/or MRI for objective evaluation. The primary end point of our study was response rate. For the evaluation of the response to concurrent chemoradiotherapy, tumour response criteria of the World Health Organization (WHO) was applied.
In this study, total 60 patients of locally advanced squamous cell carcinoma of head and neck cancer were treated. Among them 30 patients who received Paclitaxel 40 mg/m2 I.V 1 hour infusion weekly for 6 weeks, (Arm A) and the rest 30 patients received Cisplatin 30mg/m2, I.V 2 hours infusion weekly for 6 weeks (Arm B). All patients received 66Gy concurrent radiation using a Tele Cobalt 60 Machine, at the rate of 2Gy/day, 5 fractions/week, over a period of 6.5 weeks. Complete response was achieved in 63.33% cases of Arm-A where only 53.33% of cases of Arm-B showed complete response.
While partial response was achieved in 36.67% in Arm-A and 46.66% in Arm-B. Thus, the objective overall response was with no statistically significant difference. So, the results of weekly Paclitaxel schedule in the treatment of locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin schedule with no additional efficacy.
It was also observed that patients having a good performance status showed better treatment response. In Arm A, patients with Kamofsky scale of 100, 90 and 80 had a complete response rate of 100%, 66.67% and 40% respectively. In Arm B, patients with Kamofsky scale of 90, 80 and 70 had a complete response rate of 85.71%, 54.54% and 33.33% respectively. This indicates that there was a gradual decrease in complete response with decrease in performance status of the patients.
Toxicities were evaluated by history, physical examination and laboratory blood cell counts and serum tests. Laboratory and clinical toxicities were considered acute if discovered during the first 12 weeks after the initiation of therapy. The grading system was based on the Radiation Therapy Oncology Group (RTOG), acute radiation morbidity scoring criteria for the following in-field toxicities. Mucositis, nausea and skin reaction were the common treatment related toxicities in both arms.
The patients of Arm-A, suffered from vomiting less often (26.67%) than that of Arm-B (73.33%). Other toxicities like weight loss and hematological toxicities (anaemia, leucopenia) were more common in Arm-A. All the toxicities were managed effectively by conservative management.

Treatment related toxicities were more in patients treated with chemoradiation. About 81% suffering from severe toxicities effects compared to 61% of patients treated with radiation only. Two patient developed Grade I nephrotoxicity in Arm-B at first follow-up after 6 weeks of completion of treatment. So, chemotherapy given concomitantly with radiation causes more toxicity. The result of the study supports the above fact.

Survival in head and neck cancers depends on treatment response and locoregional control of the disease. Recent studies have demonstrated that concurrent chemoradiation is superior in head and neck malignancies regarding local tumor control and perhaps overall survival. This study also shows that weekly paclitaxel is suitable when cisplatin is contraindicated in the patients of renal impairment.

Conclusion
In this study the clinical response and toxicities produced by weekly low dose paclitaxel with radiation in the treatment of locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin with radiation schedule with no additional efficacy. So, concurrent chemoradiotherapy with weekly Paclitaxel is feasible when contraindication to Cisplatin for contraindicated as the patients with renal impairment.

Bibliography
1. AJCC Cancer Staging Manual. 7th edition. New York, NY : Springer-Vverlag, 2010.
2. Barrett A, Dobbs J, Morris S, Roques T. Practical Radiotherapy Planning, 4th edition, Hodder Arnold An Hachette UK Company, 2009.
3. Bomford CK, Kunkler IH, Sherrif SB. Miller Text Book of Radiotherapy, Radiation Physics, Therapy and Oncology, 6th edition, Edinburgh Churchill Livingstone, 2003; pp 355-70.
4. Cancer Registry Report 2008-2010, Distribution of patients by systemic diagnosis. Cancer Registry Report, National Institute of Cancer Research and Hospital, Mohakhali. Dhaka, pp 10-18.
5. Chu E, DeVita Jr VT. Physicians’ Cancer Chemotherapy Drug Manual 2013, 13th edition, Jones & Bartlett learning. LLC. an Ascend Learning Company, 2013; pp303-307.
6. Devita Jr VT. Lawrence TS, Rosenberg SA. Cancer Principles & Practice of Oncology, 10th edition, Lippincot Williams & Wilkins. 2015; pp 424-464.
7. Dobbs J, Banett A. Ash D. Practical radiotherapy Planning. 4th edition, UK, 2009; 88-94.
8. Gillison ML. Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancer. J Natl Cancer Inst. 2000;92:709-720.
9. GLOBCAN database. 2012., International agency for research on cancer, WHO. Cancer Incidence and Mortality <http://globo-can.iarc.fr>.
10. Halperin EC, Perez CA, Brady LW. Perez and Brady's Principles and Practice of Oncology, 6th edition, Lippincot Williams & Wilkins, 2013; 718-729.
11. Hoda HE, Azzam M. Concurrent chemoradiation in locally advanced head and neck cancers: a comparative study of weekly paclitaxel versus cisplatin-based regimen. Journal of the Egyptian nat.cancer/.nst, Vol 22,No3,2010;pp 165-173.
12. Hoque MM, Abe of Research Methodology and Biostatistics, la edition, 2009;pp 225.
13. Jahin RK, Kirar P, Gupta G, Dubey S,
Gupta SK, Goyal J. A comparative study of low dose weekly paclitaxel versus cisplatin with concurrent radiation in the treatment of locally advanced head neck cancers. Indian journal of cancer. 2019; 46, pp50-53.

14. Pazdur R, Wagman LD, Camhausen KA, Hoskins WJ. Cancer Management: A Multidisciplinary Approach, 13th edition, UBM Medica LLC, New York, 2010.

15. Perri F, Integrated therapeutic approaches in head neck cancer: the importance of multidisciplinary team management. Anticancer Agents Med. Chem. 2013; 13:834-43.

16. RTOG 0417, this protocol was designed and developed by the Radiation Therapy Oncology Group (RTOG) of the American College of Radiology. (ACR).

17. Stupp R, Weichselbaum RR, Vokes EE. Combined modality therapy of head and neck cancer. Semin Oncol. 1994; 21:349-58.

18. Symonds P, Deehan C, Mills JA, Meredith C. Walter and Miller's Textbook of Radiotherapy, 7th edition. Churchil Livingstone, London. 2012; pp341-380.

19. Talukder H, Jabeen S, Shaheen S, Islam J, Karim N, Alam AMMS 2005, Hospital based cancer registry in Bangladesh. Annual report, 1:12-13.

20. WHO. 2002. National Cancer Control Programmes: Policies and managerial guidelines. 2nd ed. Geneva: World Health Organization.